PALO ALTO, Calif., Jan. 25 /PRNewswire-FirstCall/ -- Varian Medical Systems (NYSE: VAR) today announced results for the first quarter of fiscal year 2006 ended December 30, 2005 with strong growth in net earnings, revenues, net orders and an all time record backlog. The company's Oncology Systems and X-Ray Products each contributed to robust net order growth with significant gains among emerging businesses in brachytherapy, security and inspection, and filmless X-ray imaging. "We had the strongest first quarter in the company's history," said Richard M. Levy, Varian Medical Systems' chairman and CEO.
The company reported net earnings of $41 million and net earnings per diluted share of $0.30 ($0.34 excluding approximately $5 million net of taxes or $0.04 per diluted share in stock option expenses) on revenues of $334 million in the first quarter of fiscal 2006 compared to net earnings of $40 million and net earnings per diluted share of $0.29 on revenues of $299 million in the first quarter of fiscal 2005.
Net orders were $402 million for the first quarter, up 20 percent from the year-ago quarter. Backlog at the end of the first quarter stood at $1.2 billion, 24 percent higher than at the end of the first quarter of fiscal 2005.
The company ended the first quarter with $389 million in cash and marketable securities after spending $39 million during the quarter to repurchase 895,000 shares of its common stock. The company has a new 6 million share repurchase authorization that extends through the end of calendar year 2006.
Oncology Systems' first quarter of fiscal year 2006 revenues, which includes revenues for brachytherapy products that are now reported as part of this segment, totaled $276 million, up 11 percent from results for first quarter of last fiscal year. This business recorded first-quarter net orders of $327 million, up 18 percent from the same period last year. Net orders were up 15 percent in North America and up 21 percent in international markets for the quarter.
"Orders of new products for image-guided radiotherapy (IGRT) and stereotactic treatments continued to increase as a percentage of total Oncology Systems orders during the quarter," Levy said. Varian's Dynamic Targeting® IGRT technology adjusts for movements of tumors, making it possible to treat them with higher, more effective doses while protecting more of the surrounding healthy tissue.
For comparison purposes, the first quarter of last fiscal year results for Oncology Systems have been adjusted to include the company's BrachyTherapy unit and exclude the Security and Inspection Products business.
Revenues for the X-Ray Products business, including tubes and digital flat panel detectors for filmless X-ray imaging, were $52 million for the first quarter of fiscal year 2006, up 18 percent from the year-ago quarter. "Revenue growth was driven by increased demand for filmless X-ray capability on veterinary, medical, and dental imaging equipment," Levy said. "X-ray tube revenues also increased for high power CT (computed tomography) imaging systems and for security screening."
The company's Security and Inspection Products business and the Ginzton Technology Center reported combined first quarter revenues of $6 million, down $1 million, and quarterly net orders of $20 million, up by $13 million from the year-ago period. "The company received record orders for industrial linear accelerators, driven by global demand for cargo screening and border protection," Levy said. "We are optimistic that this business is on track to generate strong order growth for the year."
For comparison purposes, the first quarter of last fiscal year results for the Other category have been adjusted to include the Security and Inspection Products business results and exclude the BrachyTherapy unit results.
"For the year, we believe that total company revenues should increase by about 14 percent above the fiscal 2005 total," Levy said. "Second-quarter revenues should grow in the mid-teens over the comparable period in fiscal year 2005.
"Excluding the impact of expensing stock options, growth in net earnings per diluted share over comparable fiscal year 2005 periods should be in the range of 17 to 18 percent for the full fiscal year and for the second quarter." The company expects that the annual impact of stock option expensing will be in the range of $0.19 to $0.22 per diluted share in fiscal year 2006 and about $0.06 for the second quarter. The company is footnoting the impact of stock option expensing on the consolidated statement of earnings attached to the company's quarterly earnings releases.
Change in Accounting
The results in the first quarter of fiscal 2006 include the impact from adoption of SFAS 123® that requires expensing of stock options and other share-based payments. The company included in its cost of revenues and operating expenses total share-based compensation expenses of approximately $8 million ($5 million net of taxes on earnings or $0.04 per diluted share).
Investor Conference Call
Varian Medical Systems is scheduled to conduct its first quarter fiscal year 2006 conference call at 2 p.m. PT today. To hear a live webcast or replay of the call, visit the investor relations page on the company's web site at http://www.varian.com/ where it will be archived for a year. To access the call via telephone, dial 1-800-299-7928 from inside the U.S. or 1-617-614-3926 from outside the U.S. and enter confirmation code 86821240. The replay can be accessed by dialing 1-888-286-8010 from inside the U.S. or 1-617-801-6888 from outside the U.S. and entering confirmation code 36456490. The telephone replay will be available through 5 p.m. PT, January 27, 2006. Additionally, certain non-GAAP information will be presented on the conference call. A reconciliation of such non-GAAP information to GAAP may be found on the investor relations page of the company's website.
Varian Medical Systems, Inc. of Palo Alto, California is the world's leading manufacturer of integrated cancer therapy systems, which are used to treat thousands of patients per day. The company is also a premier supplier of X-ray tubes and flat panel digital subsystems for imaging in medical, scientific, and industrial applications. Varian Medical Systems employs approximately 3,750 people who are located at manufacturing sites in North America and Europe and in its 56 sales and support offices around the world. Additional information is available on the company's investor relations web site at
Note regarding reconciliation:
For comparison purposes, the company makes reference to certain net earnings and net earnings per diluted share results in the first quarter of the current period which would have been consistent with GAAP if presented in prior quarters, but which are now inconsistent with GAAP due to changes in accounting standards. These results were reached by excluding non-cash, share-based compensation expenses. The company references those results to allow a better comparison of results in the current period to those in prior periods. The company's reference to these results should be considered in addition to results that are prepared under current accounting standards but should not be considered a substitute for results that are presented as consistent with GAAP.
Except for historical information, this news release contains forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning industry outlook, including market acceptance of or transition to new products or technology such as intensity modulated radiation therapy (IMRT) or image-guided radiation therapy (IGRT); growth drivers; the company's orders, revenues, backlog, or earnings growth; future financial results and any statements using the terms "should," "believe," "expect," or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company's actual results to differ materially from those anticipated. Such risks and uncertainties include demand for the company's products; the company's ability to develop and commercialize new products; the impact of competitive products and pricing; the effect of economic conditions and currency exchange rates; the company's ability to maintain or increase operating margins; the effect of changes in accounting principles; the company's ability to meet Food and Drug Administration and other regulatory requirements or product clearances; the possibility that material product liability claims could harm future revenues or require us to pay uninsured claims; the company's ability to meet demand for manufacturing capacity; the effect of environmental claims and expenses; the company's ability to protect the company's intellectual property; the company's reliance on sole or limited-source suppliers; the impact of reduced or limited demand by sole purchasers of certain X-ray tubes; the impact of managed care initiatives or other health care reforms on capital expenditures and/or third-party reimbursement levels; the potential loss of key distributors or key personnel; consolidation in the X-ray tubes market; the ability to make strategic acquisitions and to successfully integrate the acquired operations into the company's business; the risk of operations interruptions due to terrorism, disease (such as Severe Acute Respiratory Syndrome and Avian Influenza) or other events beyond the company's control; and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.
FOR INFORMATION CONTACT: Elisha Finney 650-424-6803 firstname.lastname@example.org Spencer Sias 650-424-5782 email@example.com A summary of earnings and other financial information follows. Varian Medical Systems, Inc. and Subsidiary Companies Consolidated Statements of Earnings (Unaudited) (Dollars and shares in millions, Q1 QTR Q1 QTR except per share amounts) 2006 2005 Net orders $402.3 $334.3 Oncology Systems 326.7 277.2 X-Ray Products 55.2 49.8 Other 20.4 7.3 Order backlog $1,247.0 $1,005.8 Revenues $334.2 $299.0 Oncology Systems 276.3 248.0 X-Ray Products 52.2 44.4 Other 5.7 6.6 Cost of Revenues (1) $195.4 $173.8 Gross margin 138.8 125.2 As a percent of revenues 41.5% 41.9% Operating expenses Research and development (1) 22.2 18.4 Selling, general and administrative (1) 56.8 46.2 Operating earnings 59.8 60.6 As a percent of revenues 17.9% 20.3% Interest income, net 1.6 0.5 Earnings before taxes 61.4 61.1 Taxes on earnings (1) 20.2 20.8 Net earnings (1) $41.2 $40.3 Net earnings per share - basic: (1) $0.31 $0.30 Net earnings per share - diluted: (1) $0.30 $0.29 Shares used in the calculation of net earnings per share: Average shares outstanding - basic 131.1 134.0 Average shares outstanding - diluted 135.9 139.9 (1) Includes the following amounts for expensing stock options and other share-based payments (in millions, except per share amounts) Q1 QTR Q1 QTR 2006 2005 Cost of Revenues $1.0 $-- Research and development 0.9 -- Selling, general and administrative 6.1 -- Total 8.0 -- Taxes on earnings (2.6) -- Net earnings $5.4 $-- Net earnings per share - basic $0.04 $-- Net earnings per share - diluted $0.04 $-- Varian Medical Systems, Inc. and Subsidiary Companies Consolidated Balance Sheets (In thousands) December 30, September 30, 2005 2005 (Unaudited) Assets Current assets Cash and cash equivalents $259,610 $243,086 Short-term marketable securities 125,820 135,356 Accounts receivable, net 341,285 351,899 Inventories 179,851 164,873 Other current assets 123,232 121,681 Total current assets 1,029,798 1,016,895 Property, plant and equipment 304,146 296,862 Accumulated depreciation and amortization (187,091) (182,322) Net property, plant and equipment 117,055 114,540 Long-term marketable securities 3,659 3,679 Goodwill 121,389 121,389 Other non-current assets 66,028 60,899 Total assets $1,337,929 $1,317,402 Liabilities and Stockholders' Equity Current liabilities Accounts payable $57,054 $71,007 Accrued expenses 291,752 315,287 Product warranty 38,352 39,407 Advance payments from customers 120,535 115,543 Current maturities of long term debt 2,693 2,689 Total current liabilities 510,386 543,933 Long-term accrued expenses and other 54,927 57,124 Long-term debt 57,261 57,318 Total liabilities 622,574 658,375 Stockholders' Equity Common stock 131,860 130,715 Capital in excess of par value 196,152 150,466 Retained earnings and accumulated other comprehensive loss 387,343 377,846 Total stockholders' equity 715,355 659,027 Total liabilities and stockholders' equity $1,337,929 $1,317,402
First Call Analyst:
FCMN Contact: firstname.lastname@example.org
SOURCE: Varian Medical Systems, Inc.
Web site: http://www.varian.com/